Abstract
As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS. The rapid genomic sequencing and open access data, together with advanced vaccine technology, are expected to give us more knowledge on the pathogen itself, including the host immune response as well as the plan for therapeutic vaccines in the near future. This review aims to provide a comparative view among SARS-CoV, MERS-CoV and the newly epidemic SARS-CoV-2, in the hope to gain a better understanding of the host-pathogen interaction, host immune responses, and the pathogen immune evasion strategies. This predictive view may help in designing an immune intervention or preventive vaccine for COVID-19 in the near future.
Keywords
Immune systemImmunologyVirologyPathogenCoronavirus disease 2019 (COVID-19)CoronavirusBiologyEvasion (ethics)Middle East respiratory syndrome coronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicDiseaseMedicineInfectious disease (medical specialty)
MeSH Terms
Adaptive ImmunityBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsEpidemicsHost-Pathogen InteractionsHumansImmune EvasionImmunityInnateMiddle East Respiratory Syndrome CoronavirusPneumoniaViralSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Severe Acute Respiratory SyndromeViral Vaccines
Affiliated Institutions
Related Publications
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...
Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
SUMMARY The source of the severe acute respiratory syndrome (SARS) epidemic was traced to wildlife market civets and ultimately to bats. Subsequent hunting for novel coronavirus...
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell res...
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Abstract Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002–2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. Howev...
Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak
Background: In December 2019, an outbreak of respiratory illness caused by a novel coronavirus (2019-nCoV) emerged in Wuhan, China and has swiftly spread to other parts of China...
Publication Info
- Year
- 2020
- Type
- review
- Volume
- 38
- Issue
- 1
- Pages
- 1-9
- Citations
- 1597
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1597
OpenAlex
94
Influential
382
CrossRef
Cite This
Eakachai Prompetchara,
Chutitorn Ketloy,
Tanapat Palaga
(2020).
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
Asian Pacific Journal of Allergy and Immunology
, 38
(1)
, 1-9.
https://doi.org/10.12932/ap-200220-0772
Identifiers
- DOI
- 10.12932/ap-200220-0772
- PMID
- 32105090